Navigation Links
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/14/2009

was the primary endpoint of the IMPACT trial. The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are immensely grateful to our clinical investigators and the more than 1,000 men with advanced prostate cancer who have participated in our studies over the last decade and whose courage and contribution have significantly advanced the understanding and treatment of prostate cancer and the potential role of cancer immunotherapies."

"The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient's own cancer," continued Dr. Gold.

Because the data meet the criteria and specifications outlined in its Special Protocol Assessment (SPA) agreement with the FDA, Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of this year to gain licensure of PROVENGE.

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases and approximately 28,660 men who were expected to die from the disease in 2008. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

Conference Call Scheduled for Today at 9:00 a.m. ET

Dendreon will host a conference call today at 9:00 a.m. ET. To access the live call, dial 1-877-419-6594 (domestic) or 719-325-4855 (international). The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebro
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
3. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
4. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
5. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
6. Study Shows Machine Perfusion Significantly Improves Transplant Results
7. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
8. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
9. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
(Date:5/23/2013)... May 23, 2013 The maker community ... types of inventions. They focus on learning practical skills ... community gravitate toward bringing their ideas to life via ... Movement, works on making projects using biology. Glowing Plant ... plants to make them glow with bioluminescence genes, and ...
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... host a teleconference to discuss its First Quarter 2013 ... teleconference information is provided below: Date: Thursday, ... (EDT) Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ... VS22823 For those unable to participate in ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... Cardium Health, AirLogix, and Work/Life Innovations into Next Generation ... ... Company, BEDFORD, Mass., March 4 CaseNET, Inc., a provider ... of Centene Corporation (NYSE: CNC ), has selected,the CaseNET platform ...
... - Two new independent non-executive directors added to Board with ... ... Eutick, OAM appointed independent non-executive Chairman, BRISBANE, Australia, March ... the,appointment of John Lee and Robert Williamson to the Company,s ...
... SOUTH SAN FRANCISCO, Calif., March 4 Sunesis,Pharmaceuticals, ... developing novel anticancer therapeutics, will present data at ... by the Society of,Gynecologic Oncologists (SGO). This year,s ... Tampa Convention Center in Tampa, Fla., Interim ...
Cached Biology Technology:Nurtur(TM) Selects CaseNET to Enable Integrated Health and Life Management Capabilities 2Progen Expands Board of Directors 2Progen Expands Board of Directors 3Progen Expands Board of Directors 4Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer 2
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... USC have found that a class of pharmaceuticals can ... , The drugs, known as "TSPO ligands," are currently ... at the effects of TSPO ligand in young adult ... in aged mice when pathology was quite severe," said ... of Gerontology. "TSPO ligand reduced measures of pathology and ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... antibody targeting a well known cell surface protein inhibited ... of the disease that did not respond to hormone ... UCLA Department of Urology and UCLA,s Jonsson Comprehensive Cancer ... N-cadherin, is up regulated or turned on in prostate ...
... This release is available in French . , Frank ... table would make people more aggressive, not less. After all, dont ... a game in hopes of pumping them up? And what about ... who dares take their meat away from them? Wouldnt that go ...
... Miss. A summit that,s both scientific conference and ... front lines of fighting obesity and related metabolic diseases ... sponsored by the University of Mississippi Medical Center and ... the Jackson Convention Complex. Obesity and related ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Caveman behavioral traits might kick in at Thanksgiving table before eating 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 3Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 4Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: